[go: up one dir, main page]

AR049929A1 - Metodos y composiciones para el tratamiento de afecciones oftalmicas con derivados de retinilo - Google Patents

Metodos y composiciones para el tratamiento de afecciones oftalmicas con derivados de retinilo

Info

Publication number
AR049929A1
AR049929A1 ARP050102545A ARP050102545A AR049929A1 AR 049929 A1 AR049929 A1 AR 049929A1 AR P050102545 A ARP050102545 A AR P050102545A AR P050102545 A ARP050102545 A AR P050102545A AR 049929 A1 AR049929 A1 AR 049929A1
Authority
AR
Argentina
Prior art keywords
compositions
methods
derivatives
ophthaltic
affections
Prior art date
Application number
ARP050102545A
Other languages
English (en)
Original Assignee
Sytera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34981643&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR049929(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sytera Inc filed Critical Sytera Inc
Publication of AR049929A1 publication Critical patent/AR049929A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/164—Retinal disorders, e.g. retinopathy

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Los compuestos que producen ceguera nocturna reversible pueden usarse para tratar condiciones oftálmicas asociadas con la sobreproduccion de productos de desecho que se acumulan durante el curso del ciclo visual. Se decriben métodos y composiciones que usan tales compuestos y sus derivados para tratar, entre otras, las degeneraciones y distrofias maculares o para aliviar síntomas asociados con tales condiciones oftálmicas. Los compuestos y sus derivados pueden usarse como agentes de una terapia unica o en combinacion con otros agentes o terapias.
ARP050102545A 2004-06-23 2005-06-21 Metodos y composiciones para el tratamiento de afecciones oftalmicas con derivados de retinilo AR049929A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US58229304P 2004-06-23 2004-06-23
US62969504P 2004-11-19 2004-11-19
US66090405P 2005-03-11 2005-03-11
US67240505P 2005-04-18 2005-04-18

Publications (1)

Publication Number Publication Date
AR049929A1 true AR049929A1 (es) 2006-09-13

Family

ID=34981643

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050102545A AR049929A1 (es) 2004-06-23 2005-06-21 Metodos y composiciones para el tratamiento de afecciones oftalmicas con derivados de retinilo

Country Status (26)

Country Link
US (3) US8314152B2 (es)
EP (3) EP2025336A1 (es)
JP (1) JP4855396B2 (es)
KR (1) KR100862930B1 (es)
AR (1) AR049929A1 (es)
AT (1) ATE404188T1 (es)
AU (1) AU2005262558B8 (es)
BR (1) BRPI0512569A (es)
CA (1) CA2569691C (es)
CY (1) CY1110435T1 (es)
DE (1) DE602005008970D1 (es)
DK (1) DK1768657T3 (es)
EA (1) EA011864B1 (es)
ES (1) ES2313368T3 (es)
GE (1) GEP20084520B (es)
IL (1) IL179872A (es)
LV (1) LV13564B (es)
MX (1) MXPA06014978A (es)
NO (1) NO20070408L (es)
NZ (1) NZ551955A (es)
PL (1) PL1768657T3 (es)
PT (1) PT1768657E (es)
SG (1) SG140607A1 (es)
SI (1) SI1768657T1 (es)
TW (1) TWI396532B (es)
WO (1) WO2006007314A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2324823A3 (en) 2003-03-14 2011-11-16 University of Washington Retinoid replacements and opsin agonists and methods for the use thereof
KR20060135819A (ko) 2004-02-17 2006-12-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 황반변성을 포함하는 안과질환의 관리
US7566808B2 (en) 2004-02-17 2009-07-28 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
JP2007525496A (ja) * 2004-02-17 2007-09-06 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 黄班変性症を含む眼科疾患の管理
LT2397133T (lt) 2004-06-18 2018-01-10 University Of Washington Tinklainei skirti dariniai ir būdai, skirti naudoti regėjimo susirgimų gydymui
CA2569691C (en) 2004-06-23 2010-08-17 Sirion Therapeutics, Inc. Methods and compositions for treating ophthalmic conditions with retinyl derivatives
US20060089411A1 (en) * 2004-08-07 2006-04-27 Gierhart Dennis L Treatment of Stargardt's disease and other lipofuscin disorders with combined retinaldehyde inhibitor and zeaxanthin
WO2006033734A2 (en) * 2004-08-18 2006-03-30 Sirion Therapeutics, Inc. Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders
CA2580363A1 (en) * 2004-10-28 2006-05-11 Idexx Laboratories, Inc. Compositions for controlled delivery of pharmaceutically active compounds
WO2006052860A2 (en) * 2004-11-04 2006-05-18 Sirion Therapeutics, Inc. Modulators of retinol-retinol binding protein (rbp)-transthyretin (ttr) complex formation
AU2005314039B2 (en) * 2004-12-08 2008-01-31 Revision Therapeutics, Inc. Methods, assays and compositions for treating retinol-related diseases
UA81382C2 (en) * 2005-07-11 2007-12-25 Composition for treating retinol-related diseases by modulation of retinol binding
US8114440B2 (en) * 2005-11-16 2012-02-14 Idexx Laboratories Inc. Pharmaceutical compositions for the administration of aptamers
US7754679B2 (en) * 2005-11-16 2010-07-13 Idexx Laboratories, Inc. Pharmaceutical compositions for the administration of aptamers
CA2655036A1 (en) * 2006-06-22 2007-12-27 Sirion Therapeutics, Inc. Methods and compositions for treating ophthalmic conditions via modulation of megalin activity
CA2657238A1 (en) * 2006-07-27 2008-01-31 University Of Florida Research Foundation, Inc. Compositions and methods for treating or preventing ophthalmic disease
CA2657164A1 (en) * 2006-07-27 2008-01-31 University Of Florida Research Foundation, Inc. Compositions and methods for treating or preventing ophthalmic light toxicity
WO2008013983A2 (en) * 2006-07-27 2008-01-31 University Of Florida Research Foundation, Inc. Opsin stabilizing compounds and methods of use
US8828960B2 (en) * 2007-07-17 2014-09-09 Idexx Laboratories, Inc. Amino acid vitamin ester compositions for controlled delivery of pharmaceutically active compounds
KR20160092032A (ko) 2008-02-11 2016-08-03 유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션 연령-관련 망막 기능장애의 치료 및 예방 방법
WO2009114136A2 (en) * 2008-03-12 2009-09-17 Albert Einstein College Of Medicine Of Yeshiva University Fenretinide derivatives and uses thereof as therapeutic, diagnostic and imaging agents
MX2011000545A (es) * 2008-07-14 2011-02-24 Otonomy Inc Composiciones de liberacion controlada para la modulacion de apoptosis y metodos para el tratamiento de trastornos oticos.
ES2549916T3 (es) * 2009-05-04 2015-11-03 Acucela, Inc. Composiciones para usar en el tratamiento de glaucoma o hipertensión ocular
IN2012DN00352A (es) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
WO2011034551A2 (en) 2009-09-15 2011-03-24 Qlt Inc. Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle
JP5815552B2 (ja) 2009-12-08 2015-11-17 ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ 眼疾患を治療する化合物および方法
KR20180043846A (ko) 2010-04-19 2018-04-30 노벨리언 테라퓨틱스 인코포레이티드 내인성 레티노이드 결핍과 연관된 시각 장애의 치료 또는 완화를 위한 치료 요법 및 방법
US9353063B2 (en) 2011-11-30 2016-05-31 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
PT2797601T (pt) * 2012-02-10 2018-06-27 Taiwan Liposome Co Ltd Composições farmacêuticas para reduzir complicações de esteroide ocular
CA2865935C (en) 2012-03-01 2021-12-14 Qlt Inc. Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
WO2014003850A2 (en) 2012-06-26 2014-01-03 Timothy Paul Foster Methods for treatment of ocular diseases
US9011845B2 (en) 2012-06-26 2015-04-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods for treatment of inflammatory and infectious viral diseases
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US10092393B2 (en) 2013-03-14 2018-10-09 Allotex, Inc. Corneal implant systems and methods
US10471118B2 (en) * 2014-05-30 2019-11-12 Case Western Reserve University Retinylamine derivitives for treatment of ocular disorders
CR20170160A (es) 2014-10-24 2017-06-15 Takeda Pharmaceuticals Co Compuesto heterocíclico
CN107249678B (zh) * 2014-12-19 2021-02-19 凯敏工业公司 使用离子电渗法进行生物活性分子的眼内递送
US10449090B2 (en) 2015-07-31 2019-10-22 Allotex, Inc. Corneal implant systems and methods
EP3416622B1 (en) * 2016-02-15 2023-06-28 Kemin Industries, Inc. Positively charged liposomes as lipophilic molecule carriers
US11395853B2 (en) * 2016-06-23 2022-07-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Biomimetic drug delivery of an immunomodulatory agent for the treatment of ocular conditions
EP3547899A2 (en) * 2016-12-05 2019-10-09 The Jackson Laboratory Fat droplets in retina and optic nerve as a diagnostic marker for neurodegeneration and glaucoma in humans
US11931327B2 (en) 2017-07-04 2024-03-19 Daiichi Sankyo Company, Limited Drug for retinal degenerative disease associated with photoreceptor degeneration
MX2021013609A (es) * 2019-05-06 2022-04-06 Univ California Materiales y métodos para tratar la degeneración macular relacionada con la edad.
FR3105790B1 (fr) * 2019-12-26 2022-01-14 Biophytis Composés chimiques ciblant l’œil et leur utilisation dans le traitement de maladies oculaires

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190594A (en) 1975-11-03 1980-02-26 Johnson & Johnson Retinoic acid derivatives
US4323581A (en) 1978-07-31 1982-04-06 Johnson & Johnson Method of treating carcinogenesis
US4665098A (en) 1985-03-28 1987-05-12 Mcneilab, Inc. Pharmaceutical composition of N-(4-hydroxyphenyl) retinamide having increased bioavailability
US4874795A (en) 1985-04-02 1989-10-17 Yesair David W Composition for delivery of orally administered drugs and other substances
US4673044A (en) * 1985-08-02 1987-06-16 Eastman Christensen Co. Earth boring bit for soft to hard formations
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4682663A (en) * 1986-02-18 1987-07-28 Reed Tool Company Mounting means for cutting elements in drag type rotary drill bit
US4743400A (en) 1986-09-22 1988-05-10 Mcneilab, Inc. Process for preparing retinoyl chlorides
AU6141490A (en) 1989-07-28 1991-03-11 Sloan-Kettering Institute For Cancer Research Growth factors containing vitamin a or other retinoids and uses thereof
US5814612A (en) 1991-04-09 1998-09-29 Sloan-Kettering Institute For Cancer Research Retinol derivatives and uses thereof
US6992108B1 (en) 1991-12-18 2006-01-31 The Salk Institute For Biological Studies Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor
US6050354A (en) * 1992-01-31 2000-04-18 Baker Hughes Incorporated Rolling cutter bit with shear cutting gage
US5314909A (en) 1993-03-17 1994-05-24 Merck & Co., Inc. Use of non-steroidal antiiflammatory agents in macular degeneration
US5399757A (en) 1993-07-20 1995-03-21 Ortho Pharmaceutical Corporation Process for the preparation of N-(4-hydroxyphenyl)-retinamide
US5824685A (en) 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US5596011A (en) 1995-04-06 1997-01-21 Repine; Karen M. Method for the treatment of macular degeneration
US5702357A (en) * 1995-06-07 1997-12-30 Cobe Laboratories, Inc. Extracorporeal blood processing methods and apparatus
US5706906A (en) * 1996-02-15 1998-01-13 Baker Hughes Incorporated Superabrasive cutting element with enhanced durability and increased wear life, and apparatus so equipped
US5758733A (en) * 1996-04-17 1998-06-02 Baker Hughes Incorporated Earth-boring bit with super-hard cutting elements
US5846220A (en) 1996-04-30 1998-12-08 Medtronic, Inc. Therapeutic method for treatment of Alzheimer's disease
US6034211A (en) 1996-06-03 2000-03-07 Kelly; Jeffery W. β-sheet nucleating peptidomimetics
GB9621217D0 (en) * 1996-10-11 1996-11-27 Camco Drilling Group Ltd Improvements in or relating to preform cutting elements for rotary drill bits
WO1998027972A2 (en) 1996-12-23 1998-07-02 Texas A & M University Anti-amyloidogenic agents
US5955305A (en) 1997-04-28 1999-09-21 Incyte Pharmaceuticals, Inc. Human retinoid binding protein
US5776915A (en) 1997-08-12 1998-07-07 Clarion Pharmaceuticals Inc. Phosphocholines of retinoids
UA70925C2 (uk) 1997-08-15 2004-11-15 Дюк Юнівесіті Спосіб лікування естрогенстимульованого раку
WO1999058126A1 (en) 1998-05-11 1999-11-18 The Endowment For Research In Human Biology, Inc. Use of neomycin for treating angiogenesis-related diseases
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
CA2383565A1 (en) 1999-09-14 2001-03-22 Ligand Pharmaceuticals Incorporated Rxr modulators with improved pharmacologic profile
JP2003518017A (ja) 1999-11-23 2003-06-03 ゲルハルト グラウプナー， シグナル伝達の調節
US20020031539A1 (en) 2000-08-30 2002-03-14 The Brigham And Women's Hospital, Inc. Oxidized forms of retinoic acid as ligands for peroxisome proliferator activated receptor gamma
WO2002032413A2 (en) 2000-10-17 2002-04-25 Board Of Regents, The University Of Texas System A method to incorporate n-(4-hydroxyphenyl) retinamide in liposomes
US6408958B1 (en) * 2000-10-23 2002-06-25 Baker Hughes Incorporated Superabrasive cutting assemblies including cutters of varying orientations and drill bits so equipped
JP4384409B2 (ja) 2000-12-05 2009-12-16 チルドレンズ・ホスピタル・ロス・アンジエルス バイオアベイラビリティが増加したフェンレチニドの医薬組成物、およびその使用方法
US20030032078A1 (en) 2001-01-23 2003-02-13 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of macular and retinal degenerations
EP1390343B1 (en) 2001-05-29 2009-10-14 Chebigen Co., Ltd. Novel retinoid derivatives and an anti-cancer pharmaceutical composition comprising said compounds
CA2450562A1 (en) 2001-06-22 2003-01-03 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003003987A2 (en) 2001-07-06 2003-01-16 The Ohio State University Research Foundation Solid phase synthesis of arylretinamides
WO2003007944A1 (en) 2001-07-20 2003-01-30 Qlt, Inc. Treatment of macular edema with photodynamic therapy
US20030229062A1 (en) 2001-12-07 2003-12-11 The Regents Of The University Of California Treatments for age-related macular degeneration (AMD)
US20040014131A1 (en) 2002-07-09 2004-01-22 Pfizer Inc. Assay methods
AU2003301813A1 (en) 2002-10-30 2004-06-07 University Of Kentucky Research Foundation Methods and animal model for analyzing age-related macular degeneration
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
AU2003294757A1 (en) 2002-11-29 2004-06-23 Axxima Pharmaceuticals Ag Formulations useful against hepatitis c virus infections
SI21392A (sl) 2002-12-24 2004-06-30 Vinko Kunc Postopek za avtomatsko nastavitev ojačenja izpraševalnikovega sprejemnika v brezkontaktnem identifikacijskem sistemu
MXPA05008138A (es) 2003-01-31 2006-02-17 Los Angeles Childrens Hospital Composiciones orales de fenretinida que tienen biodisponibilidad incrementada y metodos de uso de las mismas.
FI20030426A7 (fi) 2003-03-24 2004-09-25 Jaervinen Tomi Syklodekstriinikompleksit
US7178609B2 (en) * 2003-08-19 2007-02-20 Baker Hughes Incorporated Window mill and drill bit
WO2005059564A1 (en) 2003-12-11 2005-06-30 Beth Israel Deaconess Medical Center, Inc. Rbp4 in insulin sensitivity/resistance, diabetes, and obesity
WO2005077176A1 (en) 2004-02-11 2005-08-25 The Trustees Of Columbia University In The City Of New York Anthocyanin compounds and methods of use thereof
KR20060135819A (ko) * 2004-02-17 2006-12-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 황반변성을 포함하는 안과질환의 관리
US7566808B2 (en) 2004-02-17 2009-07-28 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
JP2007529434A (ja) 2004-03-17 2007-10-25 ラース マイケル ラーセン， 視覚サイクルの阻害による網膜症の予防
LT2397133T (lt) 2004-06-18 2018-01-10 University Of Washington Tinklainei skirti dariniai ir būdai, skirti naudoti regėjimo susirgimų gydymui
CA2569691C (en) 2004-06-23 2010-08-17 Sirion Therapeutics, Inc. Methods and compositions for treating ophthalmic conditions with retinyl derivatives
US7286860B2 (en) 2004-07-23 2007-10-23 Dyna Llc Systems and methods for a comfortable wireless communication device
WO2006033734A2 (en) 2004-08-18 2006-03-30 Sirion Therapeutics, Inc. Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders
WO2006052860A2 (en) 2004-11-04 2006-05-18 Sirion Therapeutics, Inc. Modulators of retinol-retinol binding protein (rbp)-transthyretin (ttr) complex formation
AU2005314039B2 (en) 2004-12-08 2008-01-31 Revision Therapeutics, Inc. Methods, assays and compositions for treating retinol-related diseases
UA81382C2 (en) 2005-07-11 2007-12-25 Composition for treating retinol-related diseases by modulation of retinol binding

Also Published As

Publication number Publication date
PL1768657T3 (pl) 2009-01-30
TW200612891A (en) 2006-05-01
US20060167088A1 (en) 2006-07-27
CA2569691C (en) 2010-08-17
CY1110435T1 (el) 2015-04-29
US20100298443A1 (en) 2010-11-25
KR20070074541A (ko) 2007-07-12
IL179872A (en) 2013-01-31
JP2008504257A (ja) 2008-02-14
DE602005008970D1 (de) 2008-09-25
US8410168B2 (en) 2013-04-02
WO2006007314A1 (en) 2006-01-19
CA2569691A1 (en) 2006-01-19
EP1768657B1 (en) 2008-08-13
ATE404188T1 (de) 2008-08-15
TWI396532B (zh) 2013-05-21
SI1768657T1 (sl) 2009-02-28
EP2277516A1 (en) 2011-01-26
DK1768657T3 (da) 2008-12-01
US20110294891A1 (en) 2011-12-01
SG140607A1 (en) 2008-03-28
EA011864B1 (ru) 2009-06-30
AU2005262558B8 (en) 2008-04-10
BRPI0512569A (pt) 2008-03-25
AU2005262558A1 (en) 2006-01-19
NO20070408L (no) 2007-03-20
LV13564B (en) 2008-02-20
EA200700109A1 (ru) 2007-10-26
PT1768657E (pt) 2008-11-25
AU2005262558B2 (en) 2008-03-20
GEP20084520B (en) 2008-10-27
NZ551955A (en) 2010-08-27
IL179872A0 (en) 2007-05-15
ES2313368T3 (es) 2009-03-01
US8314152B2 (en) 2012-11-20
EP2025336A1 (en) 2009-02-18
KR100862930B1 (ko) 2008-10-13
JP4855396B2 (ja) 2012-01-18
MXPA06014978A (es) 2007-04-25
HK1107671A1 (en) 2008-04-11
EP1768657A1 (en) 2007-04-04

Similar Documents

Publication Publication Date Title
AR049929A1 (es) Metodos y composiciones para el tratamiento de afecciones oftalmicas con derivados de retinilo
AR121843A2 (es) Formulación oftálmica y método para mejorar la presbicia
AR055075A1 (es) Metodos y composiciones para tratar trastornos oftalmicos mediante la modulacion del retinol en suero proteina enlazante de retinol en suero (rbp) y/o retinol rbp en suero
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
DOP2014000159A (es) Composiciones enriquecidas con dpa de ácidos grasos omega 3 poliinsaturados en forma de ácido libre
MX2009011473A (es) Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas.
ES2530723T3 (es) Reposición y enriquecimiento terapéuticos de la lubricación de la superficie ocular
SV2011003901A (es) Compuestos de arilo con sustituyentes heterocíclicos como inhibidores de hif
WO2007150046A3 (en) Methods and compositions for treating ophthalmic conditions via modulation of megalin activity
CL2014001158A1 (es) Compuestos derivados de piperazina alquilados; composicion farmaceutica que los comprende; proceso para preparar la composicion farmaceutica; kit y uso en el tratamiento de trastornos inmunes, cancer, enfermedades cardiovasculares, inflamacion, entre otros.
MX2009013332A (es) Inhibidores de ire-1 alfa.
EA201101576A1 (ru) Лекарственная форма токотриенол хинонов для лечения офтальмических (глазных) заболеваний
MX2014010625A (es) Inhibidores de la beta-secretasa.
MX2014008773A (es) Composiciones y metodos para el uso de ésteres de forbol.
EA201590053A1 (ru) Модуляторы пути системы комплемента и их применение
GT200600297A (es) Nuevos anticuerpos anti-madcam
CL2007000916A1 (es) Uso de alcaftadina y de acido 6,11-dihidro-11-(1-metil-4-piperidiniliden)-5h-imidazo[2,1-b][3]benzazepin-3-carboxilico, sales, n-oxidos, solvatos e hidratos para tratar sintomas de alergia ocular, inflamacion ocular y sintomas nasales de alergia ocular; composiciones oftalmicas que los comprenden; su uso y kit farmaceutico.
BR112014021602A2 (pt) uso, kit e derivado de retinal sintético para melhorar a função visual em distúrbios visuais associados com a deficiência de produção endógena de retinóide
DOP2014000174A (es) Composición y método para el diagnóstico y el tratamiento de las enfermedades asociadas a la degeneración de las neuritas
CR20130377A (es) Métodos y productos de fármaco para tratar enfermedad de alzheimer
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
MX370900B (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 cinasas.
AR059555A1 (es) Metodos para el tratamiento de degeneracion macular y condiciones oculares relacionadas
MX2022012079A (es) Metodos y composiciones para mantener la salud renal.
MX2018009173A (es) Uso de estimuladores de guanilato ciclasa soluble (sgc) para el tratamiento de esteatohepatitis no alcohólica (nash).

Legal Events

Date Code Title Description
FA Abandonment or withdrawal